ID   NCOR1_HUMAN             Reviewed;        2440 AA.
AC   O75376; B3DLF8; E9PGV6; Q86YY0; Q9UPV5; Q9UQ18;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2004, sequence version 2.
DT   10-MAY-2017, entry version 186.
DE   RecName: Full=Nuclear receptor corepressor 1;
DE            Short=N-CoR;
DE            Short=N-CoR1;
GN   Name=NCOR1; Synonyms=KIAA1047;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=9724795; DOI=10.1073/pnas.95.18.10860;
RA   Wang J., Hoshino T., Redner R.L., Kajigaya S., Liu J.M.;
RT   "ETO, fusion partner in t(8;21) acute myeloid leukemia, represses
RT   transcription by interaction with the human N-CoR/mSin3/HDAC1
RT   complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10860-10865(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Yu L.;
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=10470851; DOI=10.1093/dnares/6.3.197;
RA   Kikuno R., Nagase T., Ishikawa K., Hirosawa M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIV.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 6:197-205(1999).
RN   [4]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 974-2440 (ISOFORM 1).
RX   PubMed=10444336; DOI=10.1006/geno.1998.5694;
RA   Nagaya T., Chen K.-S., Fujieda M., Ohmori S., Richer J.K.,
RA   Horwitz K.B., Lupski J.R., Seo H.;
RT   "Localization of the human nuclear receptor co-repressor (hN-CoR) gene
RT   between the CMT1A and the SMS critical regions of chromosome
RT   17p11.2.";
RL   Genomics 59:339-341(1999).
RN   [9]
RP   INTERACTION WITH RORA.
RX   PubMed=9328355; DOI=10.1210/mend.11.11.0002;
RA   Harding H.P., Atkins G.B., Jaffe A.B., Seo W.J., Lazar M.A.;
RT   "Transcriptional activation and repression by RORalpha, an orphan
RT   nuclear receptor required for cerebellar development.";
RL   Mol. Endocrinol. 11:1737-1746(1997).
RN   [10]
RP   INTERACTION WITH TRIM28.
RX   PubMed=11013263; DOI=10.1074/jbc.M007864200;
RA   Underhill C., Qutob M.S., Yee S.P., Torchia J.;
RT   "A novel nuclear receptor corepressor complex, N-CoR, contains
RT   components of the mammalian SWI/SNF complex and the corepressor KAP-
RT   1.";
RL   J. Biol. Chem. 275:40463-40470(2000).
RN   [11]
RP   INTERACTION WITH CBFA2T3.
RX   PubMed=11533236; DOI=10.1128/MCB.21.19.6470-6483.2001;
RA   Amann J.M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N.,
RA   Downing J.R., Meyers S., Hiebert S.W.;
RT   "ETO, a target of t(8;21) in acute leukemia, makes distinct contacts
RT   with multiple histone deacetylases and binds mSin3A through its
RT   oligomerization domain.";
RL   Mol. Cell. Biol. 21:6470-6483(2001).
RN   [12]
RP   COMPONENT OF THE N-COR COMPLEX WITH TBL1X; TBL1R; NCOR2; GPS2 AND
RP   HDAC3.
RX   PubMed=11931768; DOI=10.1016/S1097-2765(02)00468-9;
RA   Zhang J., Kalkum M., Chait B.T., Roeder R.G.;
RT   "The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK
RT   pathway through the integral subunit GPS2.";
RL   Mol. Cell 9:611-623(2002).
RN   [13]
RP   INTERACTION WITH HDAC9.
RX   PubMed=12590135; DOI=10.1074/jbc.M212935200;
RA   Petrie K., Guidez F., Howell L., Healy L., Waxman S., Greaves M.,
RA   Zelent A.;
RT   "The histone deacetylase 9 gene encodes multiple protein isoforms.";
RL   J. Biol. Chem. 278:16059-16072(2003).
RN   [14]
RP   INTERACTION WITH DACH1.
RX   PubMed=14525983; DOI=10.1074/jbc.M310021200;
RA   Wu K., Yang Y., Wang C., Davoli M.A., D'Amico M., Li A., Cveklova K.,
RA   Kozmik Z., Lisanti M.P., Russell R.G., Cvekl A., Pestell R.G.;
RT   "DACH1 inhibits transforming growth factor-beta signaling through
RT   binding Smad4.";
RL   J. Biol. Chem. 278:51673-51684(2003).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH CORO2A; GPS2; HDAC3; TBL1R; TBL1X AND
RP   ZBTB33.
RX   PubMed=14527417; DOI=10.1016/j.molcel.2003.08.008;
RA   Yoon H.-G., Chan D.W., Reynolds A.B., Qin J., Wong J.;
RT   "N-CoR mediates DNA methylation-dependent repression through a methyl
RT   CpG binding protein Kaiso.";
RL   Mol. Cell 12:723-734(2003).
RN   [16]
RP   INTERACTION WITH BCL6.
RX   PubMed=15454082; DOI=10.1016/j.cell.2004.09.014;
RA   Fujita N., Jaye D.L., Geigerman C., Akyildiz A., Mooney M.R.,
RA   Boss J.M., Wade P.A.;
RT   "MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte
RT   differentiation.";
RL   Cell 119:75-86(2004).
RN   [17]
RP   INTERACTION WITH KDM3A.
RX   PubMed=16024779; DOI=10.1128/MCB.25.15.6404-6414.2005;
RA   Zhang D., Yoon H.-G., Wong J.;
RT   "JMJD2A is a novel N-CoR-interacting protein and is involved in
RT   repression of the human transcription factor achaete scute-like
RT   homologue 2 (ASCL2/Hash2).";
RL   Mol. Cell. Biol. 25:6404-6414(2005).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-224; SER-999 AND
RP   SER-2151, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2184, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [20]
RP   INTERACTION WITH HEXIM1.
RX   PubMed=17452463; DOI=10.1128/MCB.00857-06;
RA   Fu J., Yoon H.-G., Qin J., Wong J.;
RT   "Regulation of P-TEFb elongation complex activity by CDK9
RT   acetylation.";
RL   Mol. Cell. Biol. 27:4641-4651(2007).
RN   [21]
RP   INTERACTION WITH BAZ1A.
RX   PubMed=17519354; DOI=10.1210/me.2007-0095;
RA   Ewing A.K., Attner M., Chakravarti D.;
RT   "Novel regulatory role for human Acf1 in transcriptional repression of
RT   vitamin D3 receptor-regulated genes.";
RL   Mol. Endocrinol. 21:1791-1806(2007).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1472, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1472, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1111; SER-1472;
RP   SER-1977; SER-1981; SER-2184; THR-2399; SER-2436 AND SER-2438, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1472; SER-1977;
RP   SER-2151; SER-2184 AND SER-2436, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1412, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1472; SER-2184 AND
RP   SER-2438, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1195; SER-1472;
RP   SER-2151; SER-2436 AND SER-2438, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [31]
RP   INTERACTION WITH BCL6.
RX   PubMed=23911289; DOI=10.1016/j.celrep.2013.06.016;
RA   Hatzi K., Jiang Y., Huang C., Garrett-Bakelman F., Gearhart M.D.,
RA   Giannopoulou E.G., Zumbo P., Kirouac K., Bhaskara S., Polo J.M.,
RA   Kormaksson M., Mackerell A.D. Jr., Xue F., Mason C.E., Hiebert S.W.,
RA   Prive G.G., Cerchietti L., Bardwell V.J., Elemento O., Melnick A.;
RT   "A hybrid mechanism of action for BCL6 in B cells defined by formation
RT   of functionally distinct complexes at enhancers and promoters.";
RL   Cell Rep. 4:578-588(2013).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-172; SER-224; SER-1111;
RP   SER-1196; SER-1249; SER-1263; SER-1281; SER-1322; SER-1450; SER-1472;
RP   SER-1592; SER-1977; SER-2120; SER-2151 AND SER-2184, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [33]
RP   INTERACTION WITH DEAF1.
RX   PubMed=23372760; DOI=10.1371/journal.pone.0054715;
RA   Kateb F., Perrin H., Tripsianes K., Zou P., Spadaccini R.,
RA   Bottomley M., Franzmann T.M., Buchner J., Ansieau S., Sattler M.;
RT   "Structural and functional analysis of the DEAF-1 and BS69 MYND
RT   domains.";
RL   PLoS ONE 8:E54715-E54715(2013).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-224; SER-1472; SER-2136
RP   AND SER-2151, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1106, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [36]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1106, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [37]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1106, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [38]
RP   STRUCTURE BY NMR OF 433-486.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the first SANT domain from human nuclear
RT   receptor corepressor 1.";
RL   Submitted (APR-2008) to the PDB data bank.
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 2047-2065 IN COMPLEX WITH
RP   RARA AND RARA AGONIST BMS493, AND INTERACTION WITH RARA.
RX   PubMed=20543827; DOI=10.1038/nsmb.1855;
RA   le Maire A., Teyssier C., Erb C., Grimaldi M., Alvarez S.,
RA   de Lera A.R., Balaguer P., Gronemeyer H., Royer C.A., Germain P.,
RA   Bourguet W.;
RT   "A unique secondary-structure switch controls constitutive gene
RT   repression by retinoic acid receptor.";
RL   Nat. Struct. Mol. Biol. 17:801-807(2010).
CC   -!- FUNCTION: Mediates transcriptional repression by certain nuclear
CC       receptors. Part of a complex which promotes histone deacetylation
CC       and the formation of repressive chromatin structures which may
CC       impede the access of basal transcription factors. Participates in
CC       the transcriptional repressor activity produced by BCL6.
CC       {ECO:0000269|PubMed:14527417}.
CC   -!- SUBUNIT: Forms a large corepressor complex that contains SIN3A/B
CC       and histone deacetylases HDAC1 and HDAC2. This complex associates
CC       with the thyroid receptor (TR) and the retinoid acid receptor
CC       (RAR) in the absence of ligand. Interacts directly with RARA; the
CC       interaction is facilitated with RARA trimethylation. Component of
CC       the N-Cor repressor complex, at least composed of CBFA2T3, HEXIM1,
CC       NCOR1, NCOR2, HDAC3, TBL1X, TBL1XR1, CORO2A and GPS2. Interacts
CC       with ZBTB33; the interaction serves to recruit the N-CoR complex
CC       to promoter regions containing methylated CpG dinucleotides.
CC       Interacts with TRIM28 and KDM3A. Interacts (via the RD1 domain)
CC       with BAZ1A (via its N-terminal); the interaction corepresses a
CC       number of NCOR1-regulated genes. Interacts with BCL6, C1D, DACH1,
CC       HEXIM1, HDAC7, RORA, RORC, SAP30, SIAH2, SIN3A and SIN3B. May
CC       interact with DEAF1. Interacts with RXRA.
CC       {ECO:0000269|PubMed:11013263, ECO:0000269|PubMed:11533236,
CC       ECO:0000269|PubMed:12590135, ECO:0000269|PubMed:14525983,
CC       ECO:0000269|PubMed:14527417, ECO:0000269|PubMed:15454082,
CC       ECO:0000269|PubMed:16024779, ECO:0000269|PubMed:17452463,
CC       ECO:0000269|PubMed:17519354, ECO:0000269|PubMed:20543827,
CC       ECO:0000269|PubMed:23372760, ECO:0000269|PubMed:23911289,
CC       ECO:0000269|PubMed:9328355}.
CC   -!- INTERACTION:
CC       Q9UI36:DACH1; NbExp=2; IntAct=EBI-347233, EBI-347111;
CC       Q7L2E3:DHX30; NbExp=3; IntAct=EBI-347233, EBI-1211456;
CC       O15379:HDAC3; NbExp=5; IntAct=EBI-347233, EBI-607682;
CC       P42858:HTT; NbExp=3; IntAct=EBI-347233, EBI-466029;
CC       P55055:NR1H2; NbExp=6; IntAct=EBI-347233, EBI-745354;
CC       Q13133:NR1H3; NbExp=2; IntAct=EBI-347233, EBI-781356;
CC       Q9Y5X4:NR2E3; NbExp=2; IntAct=EBI-347233, EBI-7216962;
CC       Q07869:PPARA; NbExp=3; IntAct=EBI-347233, EBI-78615;
CC       P10276:RARA; NbExp=3; IntAct=EBI-347233, EBI-413374;
CC       P12755:SKI; NbExp=4; IntAct=EBI-347233, EBI-347281;
CC       Q13263:TRIM28; NbExp=4; IntAct=EBI-347233, EBI-78139;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00624}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O75376-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75376-2; Sequence=VSP_010207, VSP_010208;
CC       Name=3; Synonyms=b;
CC         IsoId=O75376-3; Sequence=VSP_046468, VSP_010207, VSP_046469,
CC                                  VSP_046470;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: The N-terminal region contains three independent domains
CC       that are capable of mediating transcriptional repression (RD1, RD2
CC       and RD3).
CC   -!- DOMAIN: The C-terminal region contains two separate nuclear
CC       receptor-interacting domains (ID1 and ID2), each of which contains
CC       a conserved sequence referred to as the CORNR box. This motif is
CC       necessary and sufficient for binding to unligated nuclear hormone
CC       receptors, while sequences flanking the CORNR box determine the
CC       precise nuclear hormone receptor specificity (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated; mediated by SIAH2 and leading to its
CC       subsequent proteasomal degradation. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the N-CoR nuclear receptor corepressors
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA82999.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF044209; AAC33550.1; -; mRNA.
DR   EMBL; AF303586; AAO32942.1; -; mRNA.
DR   EMBL; AB028970; BAA82999.2; ALT_INIT; mRNA.
DR   EMBL; AC002553; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005971; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471222; EAX04494.1; -; Genomic_DNA.
DR   EMBL; BC167431; AAI67431.1; -; mRNA.
DR   EMBL; AB019524; BAA75814.1; -; mRNA.
DR   CCDS; CCDS11175.1; -. [O75376-1]
DR   CCDS; CCDS54094.1; -. [O75376-3]
DR   CCDS; CCDS54095.1; -. [O75376-2]
DR   RefSeq; NP_001177367.1; NM_001190438.1. [O75376-3]
DR   RefSeq; NP_001177369.1; NM_001190440.1. [O75376-2]
DR   RefSeq; NP_006302.2; NM_006311.3. [O75376-1]
DR   RefSeq; XP_011522388.1; XM_011524086.2. [O75376-2]
DR   UniGene; Hs.462323; -.
DR   PDB; 2EQR; NMR; -; A=433-486.
DR   PDB; 3H52; X-ray; 2.80 A; M/N=2258-2276.
DR   PDB; 3KMZ; X-ray; 2.10 A; C/D=2047-2065.
DR   PDB; 3N00; X-ray; 2.60 A; B=2045-2065.
DR   PDB; 4MDD; X-ray; 2.40 A; C/D=2260-2274.
DR   PDB; 4WVD; X-ray; 2.90 A; C/D=2259-2275.
DR   PDBsum; 2EQR; -.
DR   PDBsum; 3H52; -.
DR   PDBsum; 3KMZ; -.
DR   PDBsum; 3N00; -.
DR   PDBsum; 4MDD; -.
DR   PDBsum; 4WVD; -.
DR   ProteinModelPortal; O75376; -.
DR   SMR; O75376; -.
DR   BioGrid; 114973; 168.
DR   DIP; DIP-29402N; -.
DR   IntAct; O75376; 66.
DR   MINT; MINT-205170; -.
DR   STRING; 9606.ENSP00000268712; -.
DR   BindingDB; O75376; -.
DR   ChEMBL; CHEMBL3038484; -.
DR   iPTMnet; O75376; -.
DR   PhosphoSitePlus; O75376; -.
DR   BioMuta; NCOR1; -.
DR   EPD; O75376; -.
DR   MaxQB; O75376; -.
DR   PaxDb; O75376; -.
DR   PeptideAtlas; O75376; -.
DR   PRIDE; O75376; -.
DR   Ensembl; ENST00000268712; ENSP00000268712; ENSG00000141027. [O75376-1]
DR   Ensembl; ENST00000395848; ENSP00000379189; ENSG00000141027. [O75376-3]
DR   Ensembl; ENST00000395851; ENSP00000379192; ENSG00000141027. [O75376-2]
DR   GeneID; 9611; -.
DR   KEGG; hsa:9611; -.
DR   UCSC; uc002gpn.4; human. [O75376-1]
DR   CTD; 9611; -.
DR   DisGeNET; 9611; -.
DR   GeneCards; NCOR1; -.
DR   HGNC; HGNC:7672; NCOR1.
DR   HPA; CAB072830; -.
DR   HPA; HPA043246; -.
DR   HPA; HPA050288; -.
DR   HPA; HPA051168; -.
DR   MIM; 600849; gene.
DR   neXtProt; NX_O75376; -.
DR   OpenTargets; ENSG00000141027; -.
DR   PharmGKB; PA31477; -.
DR   eggNOG; KOG1878; Eukaryota.
DR   eggNOG; ENOG410YDXP; LUCA.
DR   GeneTree; ENSGT00840000129748; -.
DR   HOGENOM; HOG000113746; -.
DR   HOVERGEN; HBG052587; -.
DR   InParanoid; O75376; -.
DR   KO; K04650; -.
DR   OMA; PAMPFHR; -.
DR   OrthoDB; EOG091G0379; -.
DR   PhylomeDB; O75376; -.
DR   TreeFam; TF106423; -.
DR   Reactome; R-HSA-1251985; Nuclear signaling by ERBB4.
DR   Reactome; R-HSA-1368071; NR1D1 (REV-ERBA) represses gene expression.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-3214815; HDACs deacetylate histones.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha).
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   SIGNOR; O75376; -.
DR   ChiTaRS; NCOR1; human.
DR   EvolutionaryTrace; O75376; -.
DR   GeneWiki; Nuclear_receptor_co-repressor_1; -.
DR   GenomeRNAi; 9611; -.
DR   PRO; PR:O75376; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000141027; -.
DR   CleanEx; HS_NCOR1; -.
DR   ExpressionAtlas; O75376; baseline and differential.
DR   Genevisible; O75376; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0005876; C:spindle microtubule; IDA:UniProtKB.
DR   GO; GO:0017053; C:transcriptional repressor complex; IDA:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:BHF-UCL.
DR   GO; GO:0016922; F:ligand-dependent nuclear receptor binding; IBA:GO_Central.
DR   GO; GO:0035257; F:nuclear hormone receptor binding; IPI:UniProtKB.
DR   GO; GO:0001102; F:RNA polymerase II activating transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0046966; F:thyroid hormone receptor binding; IBA:GO_Central.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:BHF-UCL.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; ISS:BHF-UCL.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0007623; P:circadian rhythm; TAS:Reactome.
DR   GO; GO:0016569; P:covalent chromatin modification; IEA:UniProtKB-KW.
DR   GO; GO:0046329; P:negative regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:1903799; P:negative regulation of production of miRNAs involved in gene silencing by miRNA; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:UniProtKB.
DR   GO; GO:2000191; P:regulation of fatty acid transport; IC:BHF-UCL.
DR   GO; GO:0072362; P:regulation of glycolytic process by negative regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0072368; P:regulation of lipid transport by negative regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0051225; P:spindle assembly; IMP:UniProtKB.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   InterPro; IPR009057; Homeobox-like.
DR   InterPro; IPR031557; N-CoR_GPS2_interact.
DR   InterPro; IPR001005; SANT/Myb.
DR   InterPro; IPR017884; SANT_dom.
DR   Pfam; PF15784; GPS2_interact; 1.
DR   Pfam; PF00249; Myb_DNA-binding; 1.
DR   SMART; SM00717; SANT; 2.
DR   SUPFAM; SSF46689; SSF46689; 2.
DR   PROSITE; PS51293; SANT; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Chromatin regulator;
KW   Coiled coil; Complete proteome; DNA-binding; Isopeptide bond; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN         1   2440       Nuclear receptor corepressor 1.
FT                                /FTId=PRO_0000055617.
FT   DOMAIN      435    486       SANT 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00624}.
FT   DOMAIN      623    674       SANT 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00624}.
FT   REGION        1    373       Interaction with ZBTB33 and HEXIM1.
FT                                {ECO:0000269|PubMed:14527417,
FT                                ECO:0000269|PubMed:17452463}.
FT   REGION      254    312       Interaction with SIN3A/B.
FT   REGION      988   1816       Interaction with ETO.
FT   REGION     1501   2440       Interaction with C1D. {ECO:0000250}.
FT   REGION     2032   2115       ID1. {ECO:0000250}.
FT   REGION     2047   2050       Required for interaction with RARA in the
FT                                absence of its ligand. {ECO:0000250}.
FT   REGION     2212   2273       ID2. {ECO:0000250}.
FT   COILED      174    216       {ECO:0000255}.
FT   COILED      299    328       {ECO:0000255}.
FT   COILED      501    557       {ECO:0000255}.
FT   MOTIF      1933   1937       CORNR box 1.
FT   MOTIF      2055   2059       CORNR box 2.
FT   MOTIF      2263   2267       CORNR box 3.
FT   COMPBIAS     58     64       Poly-Gln.
FT   COMPBIAS    593    603       Poly-Ala.
FT   COMPBIAS    607    617       Pro-rich.
FT   COMPBIAS   1032   1035       Poly-Pro.
FT   COMPBIAS   1707   1712       Poly-Ala.
FT   COMPBIAS   1952   1963       Poly-Ser.
FT   MOD_RES     172    172       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     224    224       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     999    999       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983}.
FT   MOD_RES    1111   1111       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1195   1195       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1196   1196       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1249   1249       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1263   1263       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1281   1281       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1322   1322       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1336   1336       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q60974}.
FT   MOD_RES    1367   1367       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q60974}.
FT   MOD_RES    1412   1412       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1450   1450       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1472   1472       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1592   1592       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1977   1977       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1981   1981       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    2102   2102       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9WUB5}.
FT   MOD_RES    2120   2120       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2136   2136       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2151   2151       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2184   2184       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2399   2399       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    2436   2436       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES    2438   2438       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692}.
FT   CROSSLNK   1106   1106       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK   1106   1106       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25772364}.
FT   VAR_SEQ      37    145       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_046468.
FT   VAR_SEQ     727    727       E -> EGAENSSDTESAPSPSP (in isoform 2 and
FT                                isoform 3). {ECO:0000303|PubMed:10470851,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.2}.
FT                                /FTId=VSP_010207.
FT   VAR_SEQ    1006   1007       VL -> GR (in isoform 3).
FT                                {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_046469.
FT   VAR_SEQ    1008   2440       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_046470.
FT   VAR_SEQ    1842   1961       SKHEAARLEENLRSRSAAVSEQQQLEQKTLEVEKRSVQCLY
FT                                TSSAFPSGKPQPHSSVVYSEAGKDKGPPPKSRYEEELRTRG
FT                                KTTITAANFIDVIITRQIASDKDARERGSQSSDSSSSL ->
FT                                I (in isoform 2).
FT                                {ECO:0000303|PubMed:10470851,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_010208.
FT   CONFLICT      5      5       G -> V (in Ref. 2; AAO32942).
FT                                {ECO:0000305}.
FT   CONFLICT     20     20       Y -> S (in Ref. 2; AAO32942).
FT                                {ECO:0000305}.
FT   CONFLICT     26     26       Q -> K (in Ref. 2; AAO32942).
FT                                {ECO:0000305}.
FT   CONFLICT     31     31       N -> S (in Ref. 2; AAO32942).
FT                                {ECO:0000305}.
FT   CONFLICT     33     33       R -> H (in Ref. 2; AAO32942).
FT                                {ECO:0000305}.
FT   CONFLICT    392    392       N -> S (in Ref. 2; AAO32942).
FT                                {ECO:0000305}.
FT   CONFLICT   1014   1014       V -> L (in Ref. 1; AAC33550).
FT                                {ECO:0000305}.
FT   CONFLICT   1508   1509       SS -> PP (in Ref. 1; AAC33550).
FT                                {ECO:0000305}.
FT   CONFLICT   1561   1561       R -> W (in Ref. 1; AAC33550).
FT                                {ECO:0000305}.
FT   CONFLICT   1567   1567       H -> Q (in Ref. 1; AAC33550).
FT                                {ECO:0000305}.
FT   HELIX       442    454       {ECO:0000244|PDB:2EQR}.
FT   HELIX       459    465       {ECO:0000244|PDB:2EQR}.
FT   HELIX       471    481       {ECO:0000244|PDB:2EQR}.
FT   STRAND     2048   2050       {ECO:0000244|PDB:3KMZ}.
FT   HELIX      2051   2063       {ECO:0000244|PDB:3KMZ}.
FT   HELIX      2262   2272       {ECO:0000244|PDB:4MDD}.
SQ   SEQUENCE   2440 AA;  270210 MW;  1647FE060373A125 CRC64;
     MSSSGYPPNQ GAFSTEQSRY PPHSVQYTFP NTRHQQEFAV PDYRSSHLEV SQASQLLQQQ
     QQQQLRRRPS LLSEFHPGSD RPQERRTSYE PFHPGPSPVD HDSLESKRPR LEQVSDSHFQ
     RVSAAVLPLV HPLPEGLRAS ADAKKDPAFG GKHEAPSSPI SGQPCGDDQN ASPSKLSKEE
     LIQSMDRVDR EIAKVEQQIL KLKKKQQQLE EEAAKPPEPE KPVSPPPVEQ KHRSIVQIIY
     DENRKKAEEA HKIFEGLGPK VELPLYNQPS DTKVYHENIK TNQVMRKKLI LFFKRRNHAR
     KQREQKICQR YDQLMEAWEK KVDRIENNPR RKAKESKTRE YYEKQFPEIR KQREQQERFQ
     RVGQRGAGLS ATIARSEHEI SEIIDGLSEQ ENNEKQMRQL SVIPPMMFDA EQRRVKFINM
     NGLMEDPMKV YKDRQFMNVW TDHEKEIFKD KFIQHPKNFG LIASYLERKS VPDCVLYYYL
     TKKNENYKAL VRRNYGKRRG RNQQIARPSQ EEKVEEKEED KAEKTEKKEE EKKDEEEKDE
     KEDSKENTKE KDKIDGTAEE TEEREQATPR GRKTANSQGR RKGRITRSMT NEAAAASAAA
     AAATEEPPPP LPPPPEPIST EPVETSRWTE EEMEVAKKGL VEHGRNWAAI AKMVGTKSEA
     QCKNFYFNYK RRHNLDNLLQ QHKQKTSRKP REERDVSQCE SVASTVSAQE DEDIEASNEE
     ENPEDSEVEA VKPSEDSPEN ATSRGNTEPA VELEPTTETA PSTSPSLAVP STKPAEDESV
     ETQVNDSISA ETAEQMDVDQ QEHSAEEGSV CDPPPATKAD SVDVEVRVPE NHASKVEGDN
     TKERDLDRAS EKVEPRDEDL VVAQQINAQR PEPQSDNDSS ATCSADEDVD GEPERQRMFP
     MDSKPSLLNP TGSILVSSPL KPNPLDLPQL QHRAAVIPPM VSCTPCNIPI GTPVSGYALY
     QRHIKAMHES ALLEEQRQRQ EQIDLECRSS TSPCGTSKSP NREWEVLQPA PHQVITNLPE
     GVRLPTTRPT RPPPPLIPSS KTTVASEKPS FIMGGSISQG TPGTYLTSHN QASYTQETPK
     PSVGSISLGL PRQQESAKSA TLPYIKQEEF SPRSQNSQPE GLLVRAQHEG VVRGTAGAIQ
     EGSITRGTPT SKISVESIPS LRGSITQGTP ALPQTGIPTE ALVKGSISRM PIEDSSPEKG
     REEAASKGHV IYEGKSGHIL SYDNIKNARE GTRSPRTAHE ISLKRSYESV EGNIKQGMSM
     RESPVSAPLE GLICRALPRG SPHSDLKERT VLSGSIMQGT PRATTESFED GLKYPKQIKR
     ESPPIRAFEG AITKGKPYDG ITTIKEMGRS IHEIPRQDIL TQESRKTPEV VQSTRPIIEG
     SISQGTPIKF DNNSGQSAIK HNVKSLITGP SKLSRGMPPL EIVPENIKVV ERGKYEDVKA
     GETVRSRHTS VVSSGPSVLR STLHEAPKAQ LSPGIYDDTS ARRTPVSYQN TMSRGSPMMN
     RTSDVTISSN KSTNHERKST LTPTQRESIP AKSPVPGVDP VVSHSPFDPH HRGSTAGEVY
     RSHLPTHLDP AMPFHRALDP AAAAYLFQRQ LSPTPGYPSQ YQLYAMENTR QTILNDYITS
     QQMQVNLRPD VARGLSPREQ PLGLPYPATR GIIDLTNMPP TILVPHPGGT STPPMDRITY
     IPGTQITFPP RPYNSASMSP GHPTHLAAAA SAERERERER EKERERERIA AASSDLYLRP
     GSEQPGRPGS HGYVRSPSPS VRTQETMLQQ RPSVFQGTNG TSVITPLDPT AQLRIMPLPA
     GGPSISQGLP ASRYNTAADA LAALVDAAAS APQMDVSKTK ESKHEAARLE ENLRSRSAAV
     SEQQQLEQKT LEVEKRSVQC LYTSSAFPSG KPQPHSSVVY SEAGKDKGPP PKSRYEEELR
     TRGKTTITAA NFIDVIITRQ IASDKDARER GSQSSDSSSS LSSHRYETPS DAIEVISPAS
     SPAPPQEKLQ TYQPEVVKAN QAENDPTRQY EGPLHHYRPQ QESPSPQQQL PPSSQAEGMG
     QVPRTHRLIT LADHICQIIT QDFARNQVSS QTPQQPPTST FQNSPSALVS TPVRTKTSNR
     YSPESQAQSV HHQRPGSRVS PENLVDKSRG SRPGKSPERS HVSSEPYEPI SPPQVPVVHE
     KQDSLLLLSQ RGAEPAEQRN DARSPGSISY LPSFFTKLEN TSPMVKSKKQ EIFRKLNSSG
     GGDSDMAAAQ PGTEIFNLPA VTTSGSVSSR GHSFADPASN LGLEDIIRKA LMGSFDDKVE
     DHGVVMSQPM GVVPGTANTS VVTSGETRRE EGDPSPHSGG VCKPKLISKS NSRKSKSPIP
     GQGYLGTERP SSVSSVHSEG DYHRQTPGWA WEDRPSSTGS TQFPYNPLTM RMLSSTPPTP
     IACAPSAVNQ AAPHQQNRIW EREPAPLLSA QYETLSDSDD
//
